A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors

Cancer Biology and Therapy

Volumn 11, Issue 5, 2011, Pages 464-473

  Lim, Kah Jing ^a   Bisht, Savita ^a   Bar, Eli E ^a   Maitra, Anirban ^a   Eberhart, Charles G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Curcumin; Glioblastoma; Hedgehog; IGF; Medulloblastoma; NanoCurc ; Nanocurcumin

Indexed keywords

CD133 ANTIGEN; CURCUMIN; NANOCURC; NANOPARTICLE; NOTCH RECEPTOR; SOMATOMEDIN; SONIC HEDGEHOG PROTEIN; STAT3 PROTEIN; TURMERIC; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BRAIN CANCER; BRAIN TUMOR; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENCAPSULATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MEDULLOBLASTOMA; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DOWN-REGULATION; GLIOBLASTOMA; GLYCOPROTEINS; HEDGEHOG PROTEINS; HUMANS; MEDULLOBLASTOMA; MITOSIS; NANOCAPSULES; NEOPLASTIC STEM CELLS; PEPTIDES; POLYMERS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SOMATOMEDINS; STAT3 TRANSCRIPTION FACTOR; TUMOR STEM CELL ASSAY;

EID: 79952341098     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.5.14410     Document Type: Article

References (54)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. Lyon: IARC. 2007.
2. Bengmark S, Mesa MD, Gil A. Plant-derived health: the effects of turmeric and curcuminoids. Nutr Hosp 2009; 24:273-81.
3. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65:1631-52.
4. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007; 595:1-75.
5. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23:363-98. (Pubitemid 36361976)
6. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269:199-225.
7. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci 2006; 78:2081-7.
8. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J 2009; 11:495-510.
9. Atkinson GP, Nozell SE, Benveniste ET. NFkappaB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother 2010; 10:575-86.
10. Schmidt AL, Brunetto AL, Schwartsmann G, Roesler R, Abujamra AL. Recent therapeutic advances for treating medulloblastoma: focus on new molecular targets. CNS Neurol Disord Drug Targets 2010; 9:335-48.
11. Woo MS, Jung SH, Kim SY, Hyun JW, Ko KH, Kim WK, et al. Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells. Biochem Biophys Res Commun 2005; 335:1017-25.
12. Choi BH, Kim CG, Bae YS, Lim Y, Lee YH, Shin SY. p21 Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression. Cancer Res 2008; 68:1369-77. (Pubitemid 351346844)
13. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 2007; 72:29-39. (Pubitemid 46998522)
14. Bangaru ML, Chen S, Woodliff J, Kansra S. Curcumin (diferuloylmethane) induces apoptosis and blocks migration of human medulloblastoma cells. Anticancer Res 2010; 30:499-504.
15. Dhandapani KM, Mahesh VB, Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 2007; 102:522-38. (Pubitemid 47000605)
16. Bisht S, Mizuma M, Feldmann G, Ottenhof NA, Hong SM, Pramanik D, et al. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol Cancer Ther 2010; 9:2255-64.
17. Jiang MC, Yang-Yen HF, Yen JJ, Lin JK. Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer 1996; 26:111-20. (Pubitemid 26268581)
18. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9:391-403. (Pubitemid 43668737)
19. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004; 432:396-401. (Pubitemid 39551674)
20. Lenkiewicz M, Li N, Singh SK. Culture and isolation of brain tumor initiating cells. Curr Protoc Stem Cell Biol 2009; 3:3.
21. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010; 28:5-16.
22. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67:4010-5. (Pubitemid 46815044)
23. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008; 88:808-15.
24. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010; 17:362-75.
25. Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 2010; 177:1491-502.
26. Fan X, Eberhart CG. Medulloblastoma stem cells. J Clin Oncol 2008; 26:2821-7.
27. Del Valle L, Enam S, Lassak A, Wang JY, Croul S, Khalili K, et al. Insulin-like growth factor I receptor activity in human medulloblastomas. Clin Cancer Res 2002; 8:1822-30. (Pubitemid 34633741)
28. Sandberg AC, Engberg C, Lake M, von Holst H, Sara VR. The expression of insulin-like growth factor I and insulin-like growth factor II genes in the human fetal and adult brain and in glioma. Neurosci Lett 1988; 93:114-9.
29. Glick RP, Unterman TG, Blaydes L, Hollis R. Insulinlike growth factors in central nervous system tumors. Ann NY Acad Sci 1993; 692:223-9. (Pubitemid 23299531)
30. Glick RP, Gettleman R, Patel K, Lakshman R, Tsibris JC. Insulin and insulin-like growth factor I in brain tumors: binding and in vitro effects. Neurosurgery 1989; 24:791-7. (Pubitemid 19157081)
31. Yadav A, Kalita A, Dhillon S, Banerjee K. JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3. J Biol Chem 2005; 280:31830-40. (Pubitemid 41291933)
32. Zong CS, Chan J, Levy DE, Horvath C, Sadowski HB, Wang LH. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem 2000; 275:15099-105. (Pubitemid 30337231)
33. de la Iglesia N, Puram SV, Bonni A. STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med 2009; 9:580-90.
34. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multi-potency in glioblastoma stem cells. Stem Cells 2009; 27:2383-92.
35. Dahmane N, Sanchez P, Gitton Y, Palma V, Sun T, Beyna M, et al. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development 2001; 128:5201-12. (Pubitemid 34083045)
36. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006; 66:7445-52. (Pubitemid 44289197)
37. Shahi MH, Lorente A, Castresana JS. Hedgehog signalling in medulloblastoma, glioblastoma and neuroblastoma. Oncol Rep 2008; 19:681-8. (Pubitemid 351330436)
38. Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007; 25:2524-33. (Pubitemid 47582744)
39. Bar EE, Chaudhry A, Farah MH, Eberhart CG. Hedgehog signaling promotes medulloblastoma survival via Bc/II. Am J Pathol 2007; 170:347-55. (Pubitemid 47339212)
40. Chen Y, Shu W, Chen W, Wu Q, Liu H, Cui G. Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factorkappaB and Notch 1 in Raji cells. Basic Clin Pharmacol Toxicol 2007; 101:427-33. (Pubitemid 350135350)
41. Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH. Notch-1 downregulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006; 106:2503-13. (Pubitemid 43787677)
42. Elamin MH, Shinwari Z, Hendrayani SF, Al-Hindi H, Al-Shail E, Khafaga Y, et al. Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Mol Carcinog 2010; 49:302-14.
43. Fong D, Yeh A, Naftalovich R, Choi TH, Chan MM. Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals. Cancer Lett 2010; 293:65-72.
44. Xia Y, Jin L, Zhang B, Xue H, Li Q, Xu Y. The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sci 2007; 80:2161-9. (Pubitemid 46755333)
45. Patti R, Reddy CD, Geoerger B, Grotzer MA, Raghunath M, Sutton LN, et al. Autocrine secreted insulin-like growth factor-I stimulates MAP kinase-dependent mitogenic effects in human primitive neuroectodermal tumor/medulloblastoma. Int J Oncol 2000; 16:577-84.
46. Wang JY, Del Valle L, Gordon J, Rubini M, Romano G, Croul S, et al. Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas. Oncogene 2001; 20:3857-68. (Pubitemid 32646196)
47. Kiger AA, Jones DL, Schulz C, Rogers MB, Fuller MT. Stem cell self-renewal specified by JAK-STAT activation in response to a support cell cue. Science 2001; 294:2542-5. (Pubitemid 34027293)
48. Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Ravin R, Poser SW, et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 2006; 442:823-6. (Pubitemid 44258913)
49. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264:95-8. (Pubitemid 24144493)
50. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000; 25:55-7. (Pubitemid 30257036)
51. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res 2002; 62:5551-8.
52. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal and tumorigenicity. Curr Biol 2007; 17:165-72.
53. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology 2007; 5:3.
54. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64:7011-21. (Pubitemid 39331011)